Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1895]

Multimodal AI model outperforms oncotype DX in predicting early and late...

Dr Joseph Sparano - Icahn School of Medicine at Mount Sinai, New York, USA

Multimodal AI model outperforms oncotype DX in predicting early and late distant recurrence in HR+/HER2 node negative BC ( Dr Joseph Sparano - Icahn School of Medicine at Mount Sinai, New York, USA )

Higher tumour-infiltrating lymphocytes predict better pathologic response in...

Prof Sunil Badve - Emory University, Atlanta, USA

Higher tumour-infiltrating lymphocytes predict better pathologic response in HER2-positive breast cancer ( Prof Sunil Badve - Emory University, Atlanta, USA )

Tucatinib added to trastuzumab and pertuzumab improves PFS in first-line HER2...

Dr Erika Hamilton - Sarah Cannon Research Institute, Nashville, USA

Tucatinib added to trastuzumab and pertuzumab improves PFS in first-line HER2-positive metastatic breast cancer ( Dr Erika Hamilton - Sarah Cannon Research Institute, Nashville, USA )

Oncofertility counseling and fertility preservation in premenopausal women with...

Dr Matteo Lambertini - University of Genova, Genova, Italy

Oncofertility counseling and fertility preservation in premenopausal women with early breast cancer ( Dr Matteo Lambertini - University of Genova, Genova, Italy )

Aromatase inhibitors improve disease-free survival in HR+/HER2+ early breast...

Dr Matteo Lambertini - University of Genova, Genova, Italy

Aromatase inhibitors improve disease-free survival in HR+/HER2+ early breast cancer: ALTTO 10-year follow-up ( Dr Matteo Lambertini - University of Genova, Genova, Italy )

Sacituzumab govitecan improves QoL in untreated advanced TNBC: ASCENT-03 PRO...

Dr Kevin Punie - Ziekenhuis aan de Stroom, Antwerp, Belgium

Sacituzumab govitecan improves QoL in untreated advanced TNBC: ASCENT-03 PRO analysis ( Dr Kevin Punie - Ziekenhuis aan de Stroom, Antwerp, Belgium )

AI and pathology reveal higher late recurrence risk in invasive lobular breast...

Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia

AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer ( Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia )

AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting...

Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia

AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab ( Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia )

Omitting sentinel lymph node biopsy is safe in early HR-positive, HER2-negative...

Prof Marjolein Smidt - Maastricht University Medical Center, Maastricht...

Omitting sentinel lymph node biopsy is safe in early HR-positive, HER2-negative breast cancer after 5 years ( Prof Marjolein Smidt - Maastricht University Medical Center, Maastricht, Netherlands )

Essential breast cancer medicines

Dr Didier Verhoeven, Prof Helena Earl, Prof Ahmed Magdy and Prof Luiz Gebrim

Essential breast cancer medicines ( Dr Didier Verhoeven, Prof Helena Earl, Prof Ahmed Magdy and Prof Luiz Gebrim )

ESMO 2025: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2025: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients...

Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors ( Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain )

More from ecancer